|
|
Article: Clinical Trial Data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution Presented at International ATS Conference.
- Article from:
- PR Newswire
- Article date:
- May 21, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- New product recently approved by FDA for long-term maintenance treatment of COPD bronchoconstriction; data demonstrate first nebulized formoterol fumarate provides improved lung function comparable to dry powder formoterol, enhanced patient quality of life, and positive safety profile -
NAPA, Calif., May 21 /PRNewswire/ -- Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist(TM) (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic ...